XML 20 R10.htm IDEA: XBRL DOCUMENT v3.26.1
REVENUES
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
REVENUES REVENUES
Disaggregation of Revenues
The following table summarizes our Total revenues:
Three Months Ended June 30, 2026Three Months Ended June 30, 2025
(in millions)U.S.EuropeRest of WorldTotalU.S.EuropeRest of WorldTotal
Product sales:
HIV
Biktarvy$2,981 $468 $323 $3,772 $2,799 $429 $302 $3,530 
Descovy921 23 23 967 601 24 28 653 
Genvoya236 37 16 289 322 40 16 377 
Odefsey171 58 10 239 221 66 11 298 
Symtuza - Revenue share(1)
105 30 3 138 88 33 3 124 
Yeztugo223 — 9 232 15 — — 15 
Other HIV(2)
23 24 10 56 50 33 9 92 
Total HIV4,659 640 393 5,693 4,096 624 368 5,088 
Liver Disease
Livdelzi147 20 — 167 74 4 — 78 
Sofosbuvir/Velpatasvir(3)
142 81 80 303 184 81 76 342 
Vemlidy124 13 152 289 122 13 117 252 
Other Liver Disease(4)
20 79 19 118 33 72 19 123 
Total Liver Disease433 193 251 877 413 170 211 795 
Veklury14 2 7 23 51 19 50 121 
Oncology
Cell Therapy
Tecartus29 34 8 70 41 41 9 92 
Yescarta132 139 75 346 162 154 77 393 
Total Cell Therapy161 173 83 417 203 196 86 485 
Trodelvy307 92 57 457 224 96 44 364 
Total Oncology468 265 140 873 427 291 131 849 
Other
AmBisome4 47 59 110 7 65 56 129 
Other(5)
22 8 21 51 44 8 21 73 
Total Other26 55 80 161 52 73 77 202 
Total product sales5,601 1,155 872 7,627 5,038 1,178 838 7,054 
Royalty, contract and other revenues2 169 4 176 13 10 4 27 
Total revenues$5,603 $1,324 $876 $7,803 $5,051 $1,189 $842 $7,082 
Six Months Ended June 30, 2026Six Months Ended June 30, 2025
(in millions)U.S.EuropeRest of WorldTotalU.S.EuropeRest of WorldTotal
Product sales:
HIV
Biktarvy$5,553 $905 $675 $7,133 $5,272 $804 $603 $6,679 
Descovy1,682 46 46 1,774 1,139 45 55 1,239 
Genvoya451 70 32 553 627 79 35 741 
Odefsey324 117 19 461 436 123 20 579 
Symtuza - Revenue share(1)
211 59 5 275 170 62 6 238 
Yeztugo382 — 16 397 15 — — 15 
Other HIV(2)
59 51 19 129 101 63 19 183 
Total HIV8,663 1,248 812 10,723 7,760 1,177 738 9,675 
Liver Disease
Livdelzi261 39 — 300 114 4 — 118 
Sofosbuvir/Velpatasvir(3)
283 141 162 586 351 161 175 687 
Vemlidy215 27 284 526 222 24 257 504 
Other Liver Disease(4)
35 157 40 232 61 148 35 244 
Total Liver Disease795 363 486 1,644 748 338 467 1,553 
Veklury126 17 25 167 250 41 132 423 
Oncology
Cell Therapy
Tecartus59 71 16 146 82 72 17 171 
Yescarta252 285 142 679 321 304 154 779 
Total Cell Therapy311 356 157 824 403 376 171 949 
Trodelvy560 187 112 859 405 171 81 657 
Total Oncology871 543 269 1,683 808 547 252 1,606 
Other
AmBisome11 106 131 248 13 132 123 268 
Other(5)
61 16 32 109 91 16 35 143 
Total Other72 122 163 357 104 149 158 410 
Total product sales10,527 2,292 1,755 14,574 9,669 2,251 1,747 13,668 
Royalty, contract and other revenues2 177 10 189 49 21 10 81 
Total revenues$10,529 $2,469 $1,765 $14,763 $9,719 $2,273 $1,757 $13,749 
_______________________________
(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen Ireland”).
(2)    Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.
(3)    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).
(4)    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Sovaldi, Viread and Vosevi.
(5)    Includes Cayston, Jyseleca, Letairis and Zydelig.
Revenues Recognized from Performance Obligations Satisfied in Prior Years
The following table summarizes revenues recognized from performance obligations satisfied in prior years:
Three Months EndedSix Months Ended
June 30,June 30,
(in millions)2026202520262025
Revenue share with Janssen Ireland and royalties for licenses of intellectual property$158 $153 $310 $310 
Changes in estimates(1)
$186 $126 $418 $340 
_______________________________
(1)    During the three and six months ended June 30, 2026, changes in estimates included recognition of $156 million of previously constrained revenues from the sale of certain intellectual property.
Contract Balances
The following table summarizes our contract balances:
(in millions)June 30, 2026December 31, 2025
Contract assets(1)
$756 $629 
Contract liabilities(2)
$50 $48 
_______________________________
(1)    The increase in contract assets during the six months ended June 30, 2026 primarily related to recognition of $156 million of previously constrained revenues from the sale of certain intellectual property
(2)    Future revenues recognized from contract liabilities are not expected to be material in any one year.